Journal
INFLAMMATORY BOWEL DISEASES
Volume 6, Issue 2, Pages 142-150Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/00054725-200005000-00013
Keywords
anemia; iron sucrose; erythropoietin; inflammatory bowel disease
Categories
Ask authors/readers for more resources
During the past decade relevant progress has been made in the understanding and treatment of IBD-associated anemia. Effective replacement of iron deficits has become safe by using novel intravenous iron preparations such as iron sucrose. The ability of erythropoietin to interfere with key mechanisms of myelosuppression in anemia of chronic diseases also benefits patients with IBD-associated anemia. Concerns about cost effectiveness have been raised and weighed against the potential improvement in quality of life. Gastroenterologists who are caring for IBD patients should be concerned with low hemoglobin levels, since the quality of life in these patients can be as low as in anemic patients with advanced cancer. Also provided is a structured approach to cost-effective therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available